Pharmacoeconomics & HEOR
Consultancies modeling drug value and health economics.
Market snapshot
These figures describe Healthcare & Life Sciences Research (1.8.6), the segment that Pharmacoeconomics & HEOR sits within — not Pharmacoeconomics & HEOR on its own.
No clean census code — the R&D codes here (541714 biotech, 541715 physical/engineering/life-sciences, together ~$290B) measure laboratory R&D spend, mostly in-house corporate and cross-claimed by the Healthcare and Industrials sectors, not a purchasable research-services business. The HEOR, real-world-evidence, and life-sciences market-intelligence services this segment actually means are a small slice with no code of their own.
Business model & economics
Revenue model
Project research plus recurring real-world-data and analytics subscriptions
Key economics
- Recurring revenue
- Moderate–High
- EBITDA margin
- 18–30%
- Capex intensity
- Low
real-world-data platforms recur
Characteristics
- Methods- and data-driven research, not laboratory R&D.
- Drug pipelines and payer evidence needs drive demand.
- Real-world-data platforms carry the recurring, high-value revenue.
M&A deal context
Who’s acquiring
- Real-world-data & analytics platforms
- Pharma-services consolidators
- PE-backed healthcare-research roll-ups
What’s driving deals
- Consolidation around real-world-data and analytics platforms.
- Pharma commercialization and payer-evidence demand.
- Recurring health-data assets attracting buyers.
Find Pharmacoeconomics & HEOR acquisition targets
Search Acquisera’s index for companies classified under Pharmacoeconomics & HEOR (1.8.6.3) and build a targeted deal pipeline.
Search companies